The purpose of this presentation is to highlight the recommendations made by the ACC/AHA/HFSA 2017 heart failure guidelines regarding appropriate use of sacubitril/valsartan, Ivabradine, and intravenous iron therapy. In additional, the clinical evidence that created the foundation from which these recommendations were derived will be reviewed for a more thorough understanding of the benefits associated with implementation in appropriate patients with heart failure. By reviewing the guidelines and the literature, pharmacists in attendance will be further equipped to recognize patients that may benefit from the addition of these agents to their care, recommend initiation, cessation, or avoidance of these therapies based on patient specific criteria, and participate in interdisciplinary, collaborative discussions aimed at optimizing patient care for patients with heart failure. Pharmacy technicians will be equipped with the knowledge of these medications and increased familiarity that will enhance recognition when these medications are ordered or dispensed.